Department of Anesthesiology, School of Stomatology, Fourth Military Medical University, Xi'an, China.
PLoS One. 2013 Aug 29;8(8):e72943. doi: 10.1371/journal.pone.0072943. eCollection 2013.
Neuropathic pain is an intractable clinical problem. Drug treatments such as tramadol have been reported to effectively decrease neuropathic pain by inhibiting the activity of nociceptive neurons. It has also been reported that modulating glial activation could also prevent or reverse neuropathic pain via the administration of a glial modulator or inhibitor, such as propentofylline. Thus far, there has been no clinical strategy incorporating both neuronal and glial participation for treating neuropathic pain. Therefore, the present research study was designed to assess whether coadministration of tramadol and propentofylline, as neuronal and glial activation inhibitors, respectively, would exert a synergistic effect on the reduction of rat spinal nerve ligation (SNL)-induced neuropathic pain. Rats underwent SNL surgery to induce neuropathic pain. Pain behavioral tests were conducted to ascertain the effect of drugs on SNL-induced mechanical allodynia with von-Frey hairs. Proinflammatory factor interleukin-1β (IL-1β) expression was also detected by Real-time RT-PCR. Intrathecal tramadol and propentofylline administered alone relieved SNL-induced mechanical allodynia in a dose-dependent manner. Tramadol and propentofylline coadministration exerted a more potent effect in a synergistic and dose dependent manner than the intrathecal administration of either drug alone. Real-time RT-PCR demonstrated IL-1β up-expression in the ipsilateral spinal dorsal horn after the lesion, which was significantly decreased by tramadol and propentofylline coadministration. Inhibiting proinflammatory factor IL-1β contributed to the synergistic effects of tramadol and propentofylline coadministration on rat peripheral nerve injury-induced neuropathic pain. Thus, our study provided a rationale for utilizing a novel strategy for treating neuropathic pain by blocking the proinflammatory factor related pathways in the central nervous system.
神经病理性疼痛是一种难治性临床问题。有报道称,曲马多等药物治疗通过抑制伤害感受神经元的活性,可有效减轻神经病理性疼痛。此外,通过给予神经胶质调节剂或抑制剂,如丙戊茶碱,调节神经胶质细胞的激活也可预防或逆转神经病理性疼痛。到目前为止,还没有将神经元和神经胶质参与相结合的治疗神经病理性疼痛的临床策略。因此,本研究旨在评估曲马多和丙戊茶碱分别作为神经元和神经胶质激活抑制剂共同给药是否会对减轻大鼠脊神经结扎(SNL)诱导的神经病理性疼痛产生协同作用。大鼠接受 SNL 手术以诱导神经病理性疼痛。进行疼痛行为测试,以确定药物对 SNL 诱导的机械性痛觉过敏(von-Frey 毛发)的影响。通过 Real-time RT-PCR 检测促炎因子白细胞介素-1β(IL-1β)的表达。鞘内单独给予曲马多和丙戊茶碱均可剂量依赖性地缓解 SNL 诱导的机械性痛觉过敏。与鞘内单独给予任何一种药物相比,曲马多和丙戊茶碱联合给药以协同和剂量依赖的方式发挥更强大的作用。Real-time RT-PCR 显示,损伤后同侧脊髓背角中 IL-1β表达上调,曲马多和丙戊茶碱联合给药可显著降低其表达。抑制促炎因子 IL-1β有助于曲马多和丙戊茶碱联合给药对大鼠周围神经损伤诱导的神经病理性疼痛的协同作用。因此,我们的研究为通过阻断中枢神经系统中与促炎因子相关的途径来治疗神经病理性疼痛提供了一种新的策略。